Merck and Schering-Plough Settle Lawsuits Over Vytorin and Zetia Cholesterol Pills
This article was originally published in The Pink Sheet Daily
This marks the second time in recent weeks that the drug makers have settled large-scale litigation related to the medicines.
You may also be interested in...
For a three-year period Merck will inform a committee of its board if trial results are not reported within 12 months; the agreement resolves a shareholder derivative suit claiming Schering directors caused results of the Vytorin ENHANCE trial to be suppressed.
CHICAGO - With the full presentation of the results of the failed ENHANCE study at the American College of Cardiology annual meeting, a ringing endorsement for statin use and the results of IMPROVE-IT four years away, the door seems almost closed on Merck/Schering-Plough's Zetia (ezetimibe) and Vytorin (ezetimibe/simvastatin)
Some believe unmet need refers only to rare diseases and tiny patient populations. But it is more than this. In 2020, the term sits at the heart of decision-making for drug makers – along with cost, access and value, of course.